CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to PFE

tanezumab 10 mg

Phase 3
PFIZER (PFE)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Osteoarthritis

Clinical Trial

NCT00863304

Last updated: 12/17/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Raylumis

Treatment of moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or any opioid is ineffective, not tolerated or inappropriate.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.